Pancreatic cancer genetic marker may predict outcomes with radiation therapy

Newsfeed Image, Light Gray Text On Dark Gray Background
Pancreatic cancer is one of the most difficult cancers to treat and is a leading cause of cancer-related deaths. Now, Sidney Kimmel Cancer Center – Jefferson Health and Lankenau Institute for Medical Research scientists find that a gene involved in the immune system called IDO2 plays a significant role in pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer. The discovery may help physicians provide better treatment options for patients.

“The findings could point to a therapeutic target or an important prognostic biomarker,” said George Prendergast, PhD, President and CEO of the Lankenau Institute for Medical Research (LIMR) of Main Line Health …  Read more . . .